• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
SLA
Click for more information
1.12% $4.50

SILK LASER AUSTRALIA LIMITED - Announcements

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
SLA Removal from Official List04/01/16
SLA Market Update31/12/15
SLA Appendix 4G & Corporate Governance Statement17/12/15
SLA 2015 Annual Report & Appendix 4E15/12/15
SLA 2014 Annual Report & Appendix 4E15/12/15
SLA 2013 Annual Report15/12/15
SLA 2012 Annual Report & Appendix 4E15/12/15
SLA New Investment and Intention to Lodge Accounts15/12/15
SLA Resignation of Non-Executive Director & Appendix 3Z23/09/15
SLA Suspension from Official Quotation - Annual Listing FeesPRICE SENSITIVE25/08/15
SLA United States Patent Granted for Ropren15/04/15
SLA Key United States Patent Granted18/03/15
SLA Initial Director's Interest Notice31/10/14
SLA Appointment of Dr Ian Nisbet as Non-Executive Director24/10/14
SLAAppointment of Lodge Partners as nominated adviser & broker03/04/14
AAY +Suspension from Official QuotationPRICE SENSITIVE01/03/12
SLAMarket UpdatePRICE SENSITIVE27/02/12
SLARequest for trading halt23/02/12
SLATrading HaltPRICE SENSITIVE23/02/12
SLARopren Study Published in Phytomedicine08/02/12
SLAAppendix 4C - quarterlyPRICE SENSITIVE01/02/12
SLAMarket UpdatePRICE SENSITIVE14/12/11
SLAChange of Director's Interest Notice07/12/11
SLACompany Update17/11/11
SLAResults of Meeting16/11/11
SLAMarket UpdatePRICE SENSITIVE15/11/11
SLAVisit to Australia by Leading Bioeffective A Researcher11/11/11
SLAResponse to an ASX QueryPRICE SENSITIVE08/11/11
SLAAppendix 4C - quarterlyPRICE SENSITIVE31/10/11
SLAUpdate on Poultry Trials Using CGNCPRICE SENSITIVE27/10/11
SLABioeffective A Launch in UAEPRICE SENSITIVE25/10/11
SLAAnnual Report17/10/11
SLANotice of Annual General Meeting/Proxy Form17/10/11
SLAMessage From The Executive ChairmanPRICE SENSITIVE04/10/11
SLAFull Year Statutory Accounts30/09/11
SLAMarket Update08/09/11
SLAPreliminary Final ReportPRICE SENSITIVE31/08/11
SLAAppendix 4C - quarterlyPRICE SENSITIVE01/08/11
SLAMarket UpdatePRICE SENSITIVE22/06/11
SLAMarket Update16/06/11
SLAOfficial Recognition of PolyprenolsPRICE SENSITIVE09/06/11
SLAFunding UpdatePRICE SENSITIVE30/05/11
SLAMarket UpdatePRICE SENSITIVE24/05/11
SLAEvaluation of Ropren by Professor MinushkinPRICE SENSITIVE18/05/11
SLABioeffective A Approved in the United Arab EmiratesPRICE SENSITIVE11/05/11
SLAChange of Share Registry Address10/05/11
SLAFinalisation of Litigation With The Age10/05/11
SLAAppendix 4C - quarterlyPRICE SENSITIVE02/05/11
SLAResponse of the Russian Prime MinisterPRICE SENSITIVE27/04/11
SLARopren in Liver Transplantation ?PRICE SENSITIVE19/04/11
SLAMarket UpdatePRICE SENSITIVE15/04/11
SLAAppendix 3B13/04/11
SLAVisit of Leading Russian Pharmacologist06/04/11
SLAVisit of Government Delegation31/03/11
SLAMarket Update22/03/11
SLASales and Marketing Partners Appointed17/03/11
SLAVisit of the Deputy Governor of Tomsk Region15/03/11
SLAReinstatement to Official Quotation 3/03/11PRICE SENSITIVE03/03/11
SLAHalf Yearly Report and Accounts02/03/11
SLACompany Update01/03/11
ABW +Suspension from Official QuotationPRICE SENSITIVE01/03/11
SLAResponse to ASX Appendix 4C QueryPRICE SENSITIVE07/02/11
SLAAppendix 4C - quarterlyPRICE SENSITIVE31/01/11
SLAAppendix 3B05/01/11
SLAShare Trading Policy04/01/11
SLABecoming a substantial holder23/12/10
SLAChange in substantial holding23/12/10
SLAPreliminary Report On Ropren TrialsPRICE SENSITIVE21/12/10
BPO +GI-GUARD Oral Paste -APVMA update21/12/10
SLACompletion of Capital Raising and Cleansing NoticePRICE SENSITIVE16/12/10
SLATrading HaltPRICE SENSITIVE14/12/10
SLAMarket UpdatePRICE SENSITIVE13/12/10
BPO +Response to Solagran's AGM presentation26/11/10
SLASolagran AGM Results24/11/10
SLASolagran AGM Presentation 201024/11/10
SLAReview of Ropren by Pharmexpert18/11/10
SLAMarket UpdatePRICE SENSITIVE16/11/10
BPO +Settlement of Legal Dispute with BPOPRICE SENSITIVE04/11/10
BPO +Ceasing to be a substantial holder from SLA02/11/10
SLAAppendix 4C - quarterlyPRICE SENSITIVE01/11/10
BPO +Update on Legal dispute with Solagran LimitedPRICE SENSITIVE27/10/10
SLANotice of General Meeting/Proxy Form22/10/10
SLAAnnual Report 201022/10/10
BPO +Solagran Successful in Federal Court04/10/10
SLAFull Year Statutory Accounts01/10/10
BPO +Update on Federal court proceedings with Solagran28/09/10
BPO +Update on dispute with Solagran16/09/10
BPO +Legal Proceedings Commenced By BioProspect Limited09/09/10
BPO +Dispute with Solagran LimitedPRICE SENSITIVE06/09/10
SLAPreliminary Final ReportPRICE SENSITIVE31/08/10
BPO +Update on dispute with Solagran LimtedPRICE SENSITIVE13/08/10
BPO +Notice of Dispute with BioProspect05/08/10
BPO +Dispute with Solagran Limited03/08/10
SLAInitial Director's Interest Notice30/07/10
SLAFinal Director's Interest Notice30/07/10
SLAAppendix 4C - quarterlyPRICE SENSITIVE30/07/10
BPO +Dispute with Solagran Limited29/07/10
SLABoard Changes29/07/10
SLAMarket Update - Ropren Sales in Russia20/07/10
BPO +Development Agreement with Solagran Ltd08/07/10
SLA Removal from Official List
04/01/16
SLA Market Update
31/12/15
SLA Appendix 4G & Corporate Governance Statement
17/12/15
SLA 2015 Annual Report & Appendix 4E
15/12/15
SLA 2014 Annual Report & Appendix 4E
15/12/15
SLA 2013 Annual Report
15/12/15
SLA 2012 Annual Report & Appendix 4E
15/12/15
SLA New Investment and Intention to Lodge Accounts
15/12/15
SLA Resignation of Non-Executive Director & Appendix 3Z
23/09/15
SLA Suspension from Official Quotation - Annual Listing Fees
25/08/15PRICE SENSITIVE
SLA United States Patent Granted for Ropren
15/04/15
SLA Key United States Patent Granted
18/03/15
SLA Initial Director's Interest Notice
31/10/14
SLA Appointment of Dr Ian Nisbet as Non-Executive Director
24/10/14
SLAAppointment of Lodge Partners as nominated adviser & broker
03/04/14
AAY +Suspension from Official Quotation
01/03/12PRICE SENSITIVE
SLAMarket Update
27/02/12PRICE SENSITIVE
SLARequest for trading halt
23/02/12
SLATrading Halt
23/02/12PRICE SENSITIVE
SLARopren Study Published in Phytomedicine
08/02/12
SLAAppendix 4C - quarterly
01/02/12PRICE SENSITIVE
SLAMarket Update
14/12/11PRICE SENSITIVE
SLAChange of Director's Interest Notice
07/12/11
SLACompany Update
17/11/11
SLAResults of Meeting
16/11/11
SLAMarket Update
15/11/11PRICE SENSITIVE
SLAVisit to Australia by Leading Bioeffective A Researcher
11/11/11
SLAResponse to an ASX Query
08/11/11PRICE SENSITIVE
SLAAppendix 4C - quarterly
31/10/11PRICE SENSITIVE
SLAUpdate on Poultry Trials Using CGNC
27/10/11PRICE SENSITIVE
SLABioeffective A Launch in UAE
25/10/11PRICE SENSITIVE
SLAAnnual Report
17/10/11
SLANotice of Annual General Meeting/Proxy Form
17/10/11
SLAMessage From The Executive Chairman
04/10/11PRICE SENSITIVE
SLAFull Year Statutory Accounts
30/09/11
SLAMarket Update
08/09/11
SLAPreliminary Final Report
31/08/11PRICE SENSITIVE
SLAAppendix 4C - quarterly
01/08/11PRICE SENSITIVE
SLAMarket Update
22/06/11PRICE SENSITIVE
SLAMarket Update
16/06/11
SLAOfficial Recognition of Polyprenols
09/06/11PRICE SENSITIVE
SLAFunding Update
30/05/11PRICE SENSITIVE
SLAMarket Update
24/05/11PRICE SENSITIVE
SLAEvaluation of Ropren by Professor Minushkin
18/05/11PRICE SENSITIVE
SLABioeffective A Approved in the United Arab Emirates
11/05/11PRICE SENSITIVE
SLAChange of Share Registry Address
10/05/11
SLAFinalisation of Litigation With The Age
10/05/11
SLAAppendix 4C - quarterly
02/05/11PRICE SENSITIVE
SLAResponse of the Russian Prime Minister
27/04/11PRICE SENSITIVE
SLARopren in Liver Transplantation ?
19/04/11PRICE SENSITIVE
SLAMarket Update
15/04/11PRICE SENSITIVE
SLAAppendix 3B
13/04/11
SLAVisit of Leading Russian Pharmacologist
06/04/11
SLAVisit of Government Delegation
31/03/11
SLAMarket Update
22/03/11
SLASales and Marketing Partners Appointed
17/03/11
SLAVisit of the Deputy Governor of Tomsk Region
15/03/11
SLAReinstatement to Official Quotation 3/03/11
03/03/11PRICE SENSITIVE
SLAHalf Yearly Report and Accounts
02/03/11
SLACompany Update
01/03/11
ABW +Suspension from Official Quotation
01/03/11PRICE SENSITIVE
SLAResponse to ASX Appendix 4C Query
07/02/11PRICE SENSITIVE
SLAAppendix 4C - quarterly
31/01/11PRICE SENSITIVE
SLAAppendix 3B
05/01/11
SLAShare Trading Policy
04/01/11
SLABecoming a substantial holder
23/12/10
SLAChange in substantial holding
23/12/10
SLAPreliminary Report On Ropren Trials
21/12/10PRICE SENSITIVE
BPO +GI-GUARD Oral Paste -APVMA update
21/12/10
SLACompletion of Capital Raising and Cleansing Notice
16/12/10PRICE SENSITIVE
SLATrading Halt
14/12/10PRICE SENSITIVE
SLAMarket Update
13/12/10PRICE SENSITIVE
BPO +Response to Solagran's AGM presentation
26/11/10
SLASolagran AGM Results
24/11/10
SLASolagran AGM Presentation 2010
24/11/10
SLAReview of Ropren by Pharmexpert
18/11/10
SLAMarket Update
16/11/10PRICE SENSITIVE
BPO +Settlement of Legal Dispute with BPO
04/11/10PRICE SENSITIVE
BPO +Ceasing to be a substantial holder from SLA
02/11/10
SLAAppendix 4C - quarterly
01/11/10PRICE SENSITIVE
BPO +Update on Legal dispute with Solagran Limited
27/10/10PRICE SENSITIVE
SLANotice of General Meeting/Proxy Form
22/10/10
SLAAnnual Report 2010
22/10/10
BPO +Solagran Successful in Federal Court
04/10/10
SLAFull Year Statutory Accounts
01/10/10
BPO +Update on Federal court proceedings with Solagran
28/09/10
BPO +Update on dispute with Solagran
16/09/10
BPO +Legal Proceedings Commenced By BioProspect Limited
09/09/10
BPO +Dispute with Solagran Limited
06/09/10PRICE SENSITIVE
SLAPreliminary Final Report
31/08/10PRICE SENSITIVE
BPO +Update on dispute with Solagran Limted
13/08/10PRICE SENSITIVE
BPO +Notice of Dispute with BioProspect
05/08/10
BPO +Dispute with Solagran Limited
03/08/10
SLAInitial Director's Interest Notice
30/07/10
SLAFinal Director's Interest Notice
30/07/10
SLAAppendix 4C - quarterly
30/07/10PRICE SENSITIVE
BPO +Dispute with Solagran Limited
29/07/10
SLABoard Changes
29/07/10
SLAMarket Update - Ropren Sales in Russia
20/07/10
BPO +Development Agreement with Solagran Ltd
08/07/10
refresh Created with Sketch. REFRESH
 

Top Stories

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
Alcidion inks deal with Vic health provider Peninsula for use of Miya Precision tech Alcidion Group Ltd has signed a contract worth $3.7M to enable use of its Miya Precision platform by users of Peninsula Health entities
HotCopper users react as Pancontinental Energy's trading halt lift reveals little Pancontinental has lifted a trading halt to reveal its hotly awaited potential deal with Woodside is...still just potential.
iTech inks deal with Chilean lithium giant to progress Reynolds Range iTech Minerals Ltd has signed a deal which will allow for the development of its Reynolds Range lithium project
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.